Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak purchased 13,967 shares of the firm’s stock in a transaction that occurred on Thursday, April 22nd. The shares were bought at an average price of $14.11 per share, with a total value of $197,074.37. Following the acquisition, the director now directly owns 43,300 shares of the company’s stock, valued at approximately $610,963. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Syndax Pharmaceuticals stock opened at $15.47 on Friday. The stock has a market capitalization of $746.21 million, a price-to-earnings ratio of -8.23 and a beta of 1.80. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.71 and a quick ratio of 11.71. The business has a fifty day moving average price of $22.32 and a 200-day moving average price of $21.74. Syndax Pharmaceuticals, Inc. has a 1-year low of $11.27 and a 1-year high of $27.85.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Sunday, March 7th. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. Syndax Pharmaceuticals had a negative return on equity of 77.47% and a negative net margin of 4,656.63%. The firm had revenue of $0.38 million during the quarter. On average, equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -1.85 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on the company. B. Riley reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday. Zacks Investment Research raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Robert W. Baird cut their target price on Syndax Pharmaceuticals from $39.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $27.58.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Read More: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.